FDA agrees Animal Rule pathway and PRV eligibility
Filed with ASX · · 18 pages · English
Responses significantly de-risk Galidesivir regulatory pathway – Island is now the first Australian company with an opportunity to advance drug approval under the FDA’s Animal Rule • FDA confirms the Animal Rule pathway is appropriate for developing countermeasures against Marburg • FDA advises Galidesivir would qualify for a Priority Review Voucher (PRV) on approval – PRV’s command prices up to ~
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- FDA confirms response timing for Galidesivir
- US FDA Type C meeting briefing document submitted
- FDA Meeting request granted
- FDA meeting request lodged for Galidesivir
- Preliminary Final Report
Later from Island Pharmaceuticals
- Island engages advisers to advance biodefence strategy
- Coalition acceptance to advance US procurement & stockpiling
- Options exercised raises $1million
- Additional FDA Submission completed for Galidesivir
- Island expands Galidesivir IP with US Patent Grant
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals